In this setting, preclinical data suggested that pre-treatment with enzalutamide before RLT results in more substantial DNA damage and significantly upregulated PSMA surface levels in PCa cell-line (LNCaP) [48]. Here, FOLH1 is linked to posterior cortical atrophy.